Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

I. E. Leppik, B. A. Boucher, B. J. Wilder, V. S. Murthy, C. Watridge, N. M. Graves, R. J. Rangel, C. A. Rask, P. Turlapaty

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Abstract

ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phosphatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.

Original languageEnglish (US)
Pages (from-to)456-460
Number of pages5
JournalNeurology
Volume40
Issue number3
StatePublished - Mar 1990

Fingerprint Dive into the research topics of 'Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients'. Together they form a unique fingerprint.

Cite this